As a result, UNOS developed non-standard MELD exception guidance for neuroendocrine liver metastases patients who would benefit from LT, including bilobar disease confined to the liver and not amenable to resection; tumors with portal drainage system; tumor metastatic replacement not exceeding 50% of the total liver volume; an intermediate grade by WHO classification (well-differentiated/G1 and moderately differentiated/G2 tumors); and a mitotic rate < 20 per 10 HPF, with less than 20% Ki67 marker positivity [64]. The gene discussed is MKI67; the disease is neoplasm.